Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0S9IE
|
|||
Former ID |
DIB001571
|
|||
Drug Name |
BAY1125976
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Bayer healthcare pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H21N5O
|
|||
Canonical SMILES |
C1CC(C1)(C2=CC=C(C=C2)C3=C(N4C(=N3)C=CC(=N4)C(=O)N)C5=CC=CC=C5)N
|
|||
InChI |
1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)
|
|||
InChIKey |
JBGYKRAZYDNCNV-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1402608-02-9
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01915576) Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients. U.S. National Institutes of Health. | |||
REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.